New Study in Clinical Cancer Research Shows Therapeutic Promise of Peregrine's Bavituximab With Radiation in a Lethal Brain Cancer Model

Peregrine Pharmaceuticals Awarded Second Broad U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies

Peregrine Pharmaceuticals Regains Full Compliance With Nasdaq Continued Listing Requirements

Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer

Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs

Peregrine Pharmaceuticals 1:5 Reverse Stock Split Takes Effect

Peregrine Pharmaceuticals Announces Implementation of 1:5 Reverse Stock Split to Take Effect October 19, 2009

Peregrine Pharmaceuticals Forms Anti-Viral Research Group to Oversee Its Anti-PS Infectious Disease Collaborations

Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial

Avid Bioservices Becomes U.S. West Coast Partner of Boehringer Ingelheim's Global Production Alliance Network for Biologic Contract Manufacturing Services